• LEARN MORE ABOUT KEYNOTE 695
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact
OncoSec Medical Incorporated
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact

Press Releases

Investors

Investors

  • Overview
    • Profile
    • Contacts
  • Events & Presentations
  • Analysts
  • Press Releases
    • Email Alerts
  • Financial Info
  • Stock Info
    • Quote
    • Charts
    • Historical Data
  • Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • FAQ
  • Press Releases

  • Email Alerts

OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022

Dec 05, 2022 9:00am EST

OncoSec Announces Pricing of $3.5 Million Public Offering

Nov 30, 2022 9:15am EST

OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma

Nov 15, 2022 4:45pm EST

OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

Nov 11, 2022 8:38am EST

OncoSec Announces Reverse Stock Split

Nov 08, 2022 1:22pm EST

OncoSec Announces Pipeline Prioritization and Workforce Reduction

Oct 04, 2022 5:23pm EDT

Novel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer Research

Jun 24, 2022 8:00am EDT

OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research

May 23, 2022 8:00am EDT

OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer

Apr 29, 2022 8:00am EDT

OncoSec Announces Appointment of George Chi as Chief Financial Officer

Feb 22, 2022 5:59pm EST
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...46
Next
  • Email Alerts
  • Contacts
  • RSS News Feed
logo

Sign Up for our mailing list to stay current on all of our exciting new research and developments.

Get Email Alerts
OncoSec’s investigational products have not been approved or cleared by the FDA.

Links

  • About
  • Pipeline
  • Technology
  • Partnering
  • Patients
  • Media
  • Investors
  • Contact
  • KEYNOTE 695 CLINICAL TRIAL

Contact

New Jersey Headquarters
820 Bear Tavern Road
Suite 200
Ewing, NJ 08628

R&D Laboratories
3565 General Atomics Court #100
San Diego, CA 92121

p | 855.662.6732
f | 858.430.3832

Investors@OncoSec.com


© 2023 OncoSec Medical Incorporated. All Rights Reserved. Q12-003052-01 REV E.